Serp-1 for the Treatment of Acute Coronary Syndrome

Stopped early · Phase 2

Conditions studied: Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis

In brief

Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admission and greater than 0.05 mV of presumed new ST-segment depression in at least 2 contiguous ECG leads OR, angina and per confirmatory angiogram, has been scheduled for percutaneous coronary angioplasty. The primary objective of this study is to evaluate the safety of Serp-1 injection when administered in 3 daily doses to patients undergoing conventional therapy for Acute Coronary Syndrome (ACS) requiring early intervention.

Key facts

Study ID
NCT00243308
Run by
Viron Therapeutics Inc
People needed
72
Starts
2005-10-01
Expected to finish
2008-12-01
Last updated by the study team
2009-02-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.